Norway’s sovereign wealth fund said on Monday it will abstain from voting on new board members, including the chair, at Novo Nordisk’s extraordinary shareholders’ meeting on November 14.

LONDON (Reuters) -Novo Nordisk's new CEO is set to face intense investor scrutiny this week as the Wegovy-maker shakes up its ...

The chair and six independent directors of Novo Nordisk are stepping down after a dispute with the Danish drugmaker’s ...

The Novo Nordisk Foundation in Denmark, one of the world’s leading funders of pharmaceutical and biotechnology research, is investing €21.7 million to support emerging and rising Danish researchers in ...

The Novo Foundation, through its subsidiary Novo Holdings, owns 25% of the shares and 70% of the votes in Novo Nordisk, making the election of its designees a likely formality when investors ...

Norway's sovereign wealth fund, the world's largest, said on Monday it will abstain from voting on new board members at ...

But Doustdar also seems to recognize what he has in Novo Nordisk, the 100-year-old pharma that brought insulin to the masses, ...

Novo Holdings, the investment arm of Novo Nordisk, is increasing its focus on India's healthcare sector by investing in ...

The Danish drugmaker has gone from steady to chaotic. Its fight with Pfizer to acquire Metsera is getting more and more ...